title: Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT(6) receptor antagonist.
abstract: Although recent data has shown that 5-HT(6) receptor antagonists' can enhance basal cholinergic and glutamatergic neurotransmission in the cortex and hippocampus, the distribution of this receptor within terminal regions of the dopaminergic system suggests a possible role for this receptor in the modulation of dopamine (DA). Therefore, the role of the 5-HT(6) receptor was examined in the rat striatum in the presence and absence of the DA transport inhibitor/releaser, amphetamine. Amphetamine (0.3mg/kg s.c.) induced a selective increase in extracellular DA reaching a maximum of 311.3+/-73.5% of preinjection levels. Administration of SB-271046 (1 and 10mg/kg s.c.) followed by amphetamine produced an augmentation of amphetamine-induced changes in both DA and 5-hydroxytryptamine (5-HT), reaching maximum levels of 510.1+/-110.5% and 271+/-93.4% of preinjection values, respectively. Similarly, local infusion of amphetamine (100 nM) resulted in an increase in striatal DA levels reaching a maximum of 365.7+/-73.3% of preinfusion values. However, combination treatment with SB-271046 (1mg/kg s.c.) and amphetamine produced no augmentation of amphetamine-induced increases in extracellular levels of DA or in any other neurotransmitter measured. Taken together these data indicate that the 5-HT(6) receptor is not playing a role in the tonic modulation of NA, DA, 5-HT or glutamate neurotransmission in the striatum. However, when dopaminergic neurotransmission is enhanced the 5-HT(6) receptor appears to have a modulatory influence on not only DA but also 5-HT systems. This is the first direct neurochemical evidence that the 5-HT(6) receptor may have modulatory influences on both DA and 5-HT systems in the rat striatum.
authors.affiliation: Neuroscience Research, Wyeth Ayerst, Princeton, NJ, USA. Lee_A_Dawson@gsk.com
authors.forename: Lee A
authors.initials: LA
authors.lastname: Dawson
authors.forename: Huy Q
authors.initials: HQ
authors.lastname: Nguyen
authors.forename: Ping
authors.initials: P
authors.lastname: Li
mesh_terms: D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D015259:Dopamine Agents / Q000494:pharmacology*; D004357:Drug Synergism; D005110:Extracellular Space / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D008297:Male; D017551:Microdialysis; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011985:Receptors, Serotonin / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D013876:Thiophenes / Q000494:pharmacology*
chemical_list: D015259:Dopamine Agents; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D013449:Sulfonamides; D013876:Thiophenes; C097216:serotonin 6 receptor; D012701:Serotonin; D018698:Glutamic Acid; D000661:Amphetamine; C117443:SB 271046; D004298:Dopamine; D009638:Norepinephrine